BBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BridgeBio Pharma Inc (BBIO) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong long-term growth potential, supported by positive analyst ratings, increasing revenue growth, and heavy buying by Congress members. While short-term technical indicators suggest some bearish momentum, the long-term outlook remains favorable.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 23.484, suggesting oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating an upward trend in the long term. The stock is trading near its support level of 72.384, with resistance at 78.871.
Congress members have made 3 purchase transactions recently, indicating confidence in the stock.
Analysts have consistently raised price targets, with a median target above $90, suggesting significant upside potential.
The company's pipeline and products like Attruby are well-positioned for growth, with no generic competition expected until 2028.
The stock experienced a -3.72% regular market decline, reflecting short-term bearish sentiment.
Net income and EPS have declined YoY, which may concern some investors.
Ongoing tafamidis litigation introduces some uncertainty.
In Q4 2025, revenue increased by 2521.18% YoY to $154.18M, indicating strong growth. However, net income dropped by -27.24% YoY to -$192.86M, and EPS fell by -28.57% YoY to -1. Gross margin improved significantly to 94.74%, up 46.72% YoY, showcasing operational efficiency.
Analysts are overwhelmingly positive on BBIO, with multiple firms maintaining Outperform or Buy ratings. Price targets range from $81 to $125, with a median target in the $90s. Analysts highlight strong growth in Attruby sales, a robust drug pipeline, and limited competition in key markets as reasons for optimism.
